DR. REDDY’S LABORATORIES LIMITED
boothcheck covers DR. REDDY’S LABORATORIES LIMITED (RDY) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed June 28, 2026.
Dr. Reddy's earns a strong 22.3 percent operating margin on a generics-heavy revenue base, and at $13.30 per ADR the price is supported by peer multiples while the earnings-power and growth-DCF lenses call it expensive. The disagreement is the whole story. The near-term problem is concrete: North America revenue fell 22 percent in fiscal 2026 as the high-margin lenalidomide generic, the company's authorized version of Revlimid, rolled off. That single product cliff dragged a fourth quarter that
Is RDY overvalued? See what's priced in →
238 institutional managers reported holding RDY in 13F filings for the quarter ended 2026-03-31. Together they hold about 14% of the company; the top 10 hold 10%. 33 opened new positions that quarter. Held by BlackRock, Morgan Stanley, Renaissance Technologies, among others. On the short side, 22.9M shares were sold short as of the 2026-06-15 count, about 3% of shares outstanding (16.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
RDY's share count is about flat over the past five years. It pays a dividend, and has paid one every year in our records (10 and counting). Cash returned over the past three years: $159.31M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.